Yun Hui Choi
Research Subjects
Yun Hui Choi has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Cheolju Lee
Chemical and Biological Integrative Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea
2 shared publications Eunho Chun
Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, Republic of Korea
2 shared publicationsGeunyeol Jeong
Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, Republic of Korea
2 shared publicationsGil Joon Suh
Department of Emergency Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
2 shared publicationsHee Kyeong Yoon
R&D Center, MirimGENE, Incheon, Republic of Korea
2 shared publications- Hee-Sung Ahn
Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 5 February 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (3) , 665
Author Correction: Highly secreted tryptophanyl tRNA synthetase 1 as a potential theranostic target for hypercytokinemic severe sepsis
- 5 February 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (3) , 665
Open AccessAuthor Correction: Highly secreted tryptophanyl tRNA synthetase 1 as a potential theranostic target for hypercytokinemic severe sepsis
- Open Access
- 14 December 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (1) , 40-63
Highly secreted tryptophanyl tRNA synthetase 1 as a potential theranostic target for hypercytokinemic severe sepsis
Despite intensive clinical and scientific efforts, the mortality rate of sepsis remains high due to the lack of precise biomarkers for patient stratification and therapeutic guidance. Secreted human tryptophanyl-tRNA synthetase 1 (WARS1), an endogenous ligand for Toll-like receptor (TLR) 2 and TLR4 against infection, activates the genes that signify the hyperinflammatory sepsis phenotype. High plasma WARS1 levels stratified the early death of critically ill patients with sepsis, along with elevated levels of cytokines, chemokines, and lactate, as well as increased numbers of absolute neutrophils and monocytes, and higher Sequential Organ Failure Assessment (SOFA) scores. These symptoms were recapitulated in severely ill septic mice with hypercytokinemia. Further, injection of WARS1 into mildly septic mice worsened morbidity and mortality. We created an anti-human WARS1-neutralizing antibody that suppresses proinflammatory cytokine expression in marmosets with endotoxemia. Administration of this antibody into severe septic mice attenuated cytokine storm, organ failure, and early mortality. With antibiotics, the antibody almost completely prevented fatalities. These data imply that blood-circulating WARS1-guided anti-WARS1 therapy may provide a novel theranostic strategy for life-threatening systemic hyperinflammatory sepsis.
- 14 December 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (1) , 40-63
Open AccessHighly secreted tryptophanyl tRNA synthetase 1 as a potential theranostic target for hypercytokinemic severe sepsis
Despite intensive clinical and scientific efforts, the mortality rate of sepsis remains high due to the lack of precise biomarkers for patient stratification and therapeutic guidance. Secreted human tryptophanyl-tRNA synthetase 1 (WARS1), an endogenous ligand for Toll-like receptor (TLR) 2 and TLR4 against infection, activates the genes that signify the hyperinflammatory sepsis phenotype. High plasma WARS1 levels stratified the early death of critically ill patients with sepsis, along with elevated levels of cytokines, chemokines, and lactate, as well as increased numbers of absolute neutrophils and monocytes, and higher Sequential Organ Failure Assessment (SOFA) scores. These symptoms were recapitulated in severely ill septic mice with hypercytokinemia. Further, injection of WARS1 into mildly septic mice worsened morbidity and mortality. We created an anti-human WARS1-neutralizing antibody that suppresses proinflammatory cytokine expression in marmosets with endotoxemia. Administration of this antibody into severe septic mice attenuated cytokine storm, organ failure, and early mortality. With antibiotics, the antibody almost completely prevented fatalities. These data imply that blood-circulating WARS1-guided anti-WARS1 therapy may provide a novel theranostic strategy for life-threatening systemic hyperinflammatory sepsis.